# Antibodies as Drugs: The Art in Antibody Engineering

> **NIH NIH R13** · KEYSTONE SYMPOSIA · 2024 · $11,000

## Abstract

ABSTRACT
Support is requested for a Keystone Symposia conference entitled Antibodies as Drugs: The Art in Antibody
Engineering, organized by Drs. Laura Walker and Paul W. H. I. Parren. The conference will be held in
Breckenridge, Colorado from May 5-8, 2024.
Antibodies have become the most successful and versatile class of biological drugs with well over 100
therapeutic antibodies approved for human use. Antibody engineering for optimized and novel functionalities is
providing unprecedented opportunities in our quest to develop innovative treatments for a wide variety of
diseases. In recent years, engineered antibody formats have matured from research to clinical stage molecules
with engineered antibodies currently representing about 40% of the 1,000+ antibodies in clinical development.
Therefore, this Keystone Symposia conference will review the translation of fundamental insights in both
antibody and pathological mechanisms into next generation therapeutics and will discuss the opportunities and
challenges ahead.

## Key facts

- **NIH application ID:** 10906688
- **Project number:** 1R13AI183727-01
- **Recipient organization:** KEYSTONE SYMPOSIA
- **Principal Investigator:** TERRY L. SHEPPARD
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $11,000
- **Award type:** 1
- **Project period:** 2024-04-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10906688

## Citation

> US National Institutes of Health, RePORTER application 10906688, Antibodies as Drugs: The Art in Antibody Engineering (1R13AI183727-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10906688. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*